Cost-effectiveness of 2-[18F]FDG-PET/CT versus CE-CT for response monitoring in patients with metastatic breast cancer: a register-based comparative study

MLA

Mohammad Naghavi-Behzad, et al. “Cost-Effectiveness of 2-[18F]FDG-PET/CT versus CE-CT for Response Monitoring in Patients with Metastatic Breast Cancer: A Register-Based Comparative Study.” Scientific Reports, vol. 13, no. 1, Sept. 2023, pp. 1–10. EBSCOhost, https://doi.org/10.1038/s41598-023-43446-7.

APA

Mohammad Naghavi-Behzad, Oke Gerke, Annette Raskov Kodahl, Marianne Vogsen, Jon Thor Asmussen, Wolfgang Weber, Malene Grubbe Hildebrandt, & Kristian Kidholm. (2023). Cost-effectiveness of 2-[18F]FDG-PET/CT versus CE-CT for response monitoring in patients with metastatic breast cancer: a register-based comparative study. Scientific Reports, 13(1), 1–10. https://doi.org/10.1038/s41598-023-43446-7

Chicago

Mohammad Naghavi-Behzad, Oke Gerke, Annette Raskov Kodahl, Marianne Vogsen, Jon Thor Asmussen, Wolfgang Weber, Malene Grubbe Hildebrandt, and Kristian Kidholm. 2023. “Cost-Effectiveness of 2-[18F]FDG-PET/CT versus CE-CT for Response Monitoring in Patients with Metastatic Breast Cancer: A Register-Based Comparative Study.” Scientific Reports 13 (1): 1–10. doi:10.1038/s41598-023-43446-7.